Based on this data monoclonal antibody targeting Gal3 is being tested for AD in clinical phase 1b/2a (TrueBinding Inc.; ClinicalTrials.gov identifiers: NCT05074498 and NCT05476783) with no published phase 2 results yet. This evidence concerns the gene LGALS3 and Alzheimer disease.